VSTM - verastem.com Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Verastem, Inc. (VSTM)

Compliance with environmental regulations for laboratory waste disposal correlates with the price-to-earnings ratio relative to the EPS growth forecast, where the 0.00 mark characterizes this parameter. A transparent inhibitor pipeline and management's fundraising expertise ensure operational resilience. High scalability driven by patents for innovative formulas allows Verastem, Inc. (VSTM) to plan global sales with minimal costs.

VSTM: verastem.com Price/Earnings to Growth Multiple 07/04/2022 - 11/10/2026

Metric breakdowns and analytics for Verastem, Inc. (VSTM)

- market value and analyst target forecast:
Price Rate Chart Verastem Oncology|VSTM - Consensus Target
- market capitalization statistics:
Market Value Verastem Inc|VSTM - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share Verastem|VSTM - Company Net Assets|Market Cap to Book Value Multiple verastem.com|VSTM - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Verastem, Inc.|VSTM - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital verastem.com|VSTM - Company Aggregate Debts|Debt to Net Assets Verastem Inc|VSTM - Company Long-Term Debts|Short-Term Debt Verastem|Intermediate Liquidity Ratio verastem.com
- earnings and valuation multiples information:
VSTM - Net Profit|Expected Net Profit Verastem, Inc.|VSTM - P/E Multiple|Price to Future Earnings Ratio Verastem Corp|VSTM - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Verastem Inc|VSTM - Operating profit before deduction of amortization|Earnings per share for the last four quarters Verastem|VSTM - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months verastem.com|VSTM - Earnings growth in current year|Expected net earnings per share growth next year Verastem, Inc.
General company analysis:Verastem, Inc.
Signature product of verastem.com

The specific nature of Verastem, Inc. (VSTM) in developing proprietary oncology drugs makes the PEG ratio a key indicator for valuing future cash flows. This ratio compares the current earnings multiple with net income growth; a value below one signals that the asset is undervalued, allowing investors to identify potentially high-growth stocks with efficient management.

Competing companies

Genmab AS (GMAB) - Price to Net Income Growth Ratio|Exelixis Corp - Price/Earnings to Growth Multiple|Nuvalent Therapeutics (NUVL) - Price to Earnings Adjusted for Growth Rate|KYMR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IDYA (ideayabio.com)|ELVN (Enliven Therapeutics, Inc.) - Price/Earnings to Growth Multiple|ORIC: Company Value to Earnings Growth Ratio|RLAY (Relay Pharma) - PEG Multiple|PEG Multiple Nurix Corp|Price/Earnings to Growth Ratio Tyra Biosciences, Inc. (TYRA)|GLUE (monterosatx.com) - Growth-Adjusted Payback Ratio|PEG Multiple CGEM (Cullinan Therapeutics, Inc.)|Price to Net Income Growth Ratio Immuneering Corp|C4 Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Black Diamond Therapeutics, Inc|RPTX (Repare Therapeutics) - Price/Earnings to Growth Multiple|PMVP: Company Value to Earnings Growth Ratio|KPTI (Karyopharm Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Propanc Biopharma, Inc. PPCB|PEG Multiple BGMS|aadibio.com - Growth-Adjusted P/E Ratio|Aileron Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BPMC|GLYC: Price/Earnings to Growth Multiple|SpringWorks Therapeutics Inc. - Company Value to Earnings Growth Ratio